Sven Süfke
University of Lübeck
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sven Süfke.
JAMA Dermatology | 2014
Michael Kasperkiewicz; Sven Süfke; Enno Schmidt; Detlef Zillikens
Report of Cases Two consecutively recruited patients with atopic dermatitis (AD) (a man in his 50s [patient 1] and a man in his 40s [patient 2]) displayed high serum IgE levels of 40 848 and 111 696 μg/L (to convert to milligrams per liter, multiply by 0.001), Scoring Atopic Dermatitis (SCORAD) scores of 66 and 77, respectively, and a history of no substantial or long-term SCORAD reduction after use of topical corticosteroids and calcineurin inhibitors, UV light therapy, systemic corticosteroids, and cyclosporine A.
Journal Der Deutschen Dermatologischen Gesellschaft | 2018
Franziska Hübner; Michael Kasperkiewicz; Diana Knuth-Rehr; Iakov Shimanovich; Joachim Hübner; Sven Süfke; Philip Muck; Detlef Zillikens; Enno Schmidt
While depletion of circulating autoantibodies using immunoadsorption (IA) is an established therapeutic approach in patients with pemphigus vulgaris, IA has only sporadically been used in other autoimmune bullous disorders. Although bullous pemphigoid (BP) usually responds well to topical and systemic corticosteroids, rapid depletion of serum autoantibodies may be an effective adjuvant treatment option in patients with severe and/or refractory disease.
International Journal of Cardiology | 2012
Birgit Harbeck; Alexander Joost; Walter Lehne; Anja Böhm; Sven Süfke; Stephan Werth; Hendrik Lehnert; Christian S. Haas
Hypertension is a frequent condition in the general population, and may lead to severe end organ damage. Various endocrine disorders cause hypertension, requiring specific attention and treatment. Paragangliomas (PGLs) are catecholamine producing chromaffin cell tumors developing from the sympathetic and parasympathetic ganglia throughout the abdomen and head and neck area, respectively. When arising from the adrenal gland, PGLs are referred to as pheochromocytomas (PHEOs). PGLs/PHEOs have an incidence of 1–2 per 100,000 and a prevalence of 0.1–0.4% in patients with hypertension [1]. They synthesize and secrete catecholamines and more rarely dopamine, causing a variety of clinical symptoms. The classic triad of symptoms consists of episodic headache (90%), sweating (60–70%) and heart palpitations. Moreover, most patients with PGL/PHEO suffer from paroxysmal or sustained hypertension. However, 5–15% of patients present with normal blood pressure. Other symptoms might be dyspnea, weakness, weight loss, psychiatric disorders or alterations in carbohydrate metabolism (hyperglycemia, insulin resistance). Several genetic disorders are associated with PHEOs (MEN 2a/b, von Hippel– Lindau disease, SDH gene mutations, MAXmutations, Neurofibromatosis Type 1). We here report the case of a hypertensive patient with a PHEO presentation with myositis and perimyocarditis. A 76 year-old female patient with a history of hypertension was admitted to the hospital with progressive severe pain and weakness of the shoulder girdle and thighs for several weeks. Laboratory
Journal Der Deutschen Dermatologischen Gesellschaft | 2018
Franziska Hübner; Michael Kasperkiewicz; Diana Knuth-Rehr; Iakov Shimanovich; Joachim Hübner; Sven Süfke; Philip Muck; Detlef Zillikens; Enno Schmidt
Mittels Immunadsorption (IA) können Immunglobuline und Immunkomplexe aus dem Plasma entfernt werden. Während dieses therapeutische Verfahren beim Pemphigus vulgaris bereits etabliert ist, wird es bei anderen blasenbildenden Autoimmundermatosen bislang nur sporadisch eingesetzt. Das bullöse Pemphigoid (BP) spricht zwar meist gut auf eine Therapie mit topischen und systemischen Kortikosteroiden an, jedoch könnte bei Patienten mit ausgedehnten Läsionen oder bei einem Rezidiv die rasche Reduktion der pathogenen Autoantikörper eine effektive adjuvante Therapie darstellen.
Therapeutic Apheresis and Dialysis | 2017
Sven Süfke; Hendrik Lehnert; Ingrid Uhlenbusch-Körwer; Frank Gebauer
Therapeutic apheresis and immunoadsorption are used to deplete efficiently pathogenic autoantibodies in crises in several acute autoimmune driven diseases. This prospective, non‐comparative cohort study was conducted at a single study center under standardized conditions in 10 healthy volunteers. Efficient immunoglobulin G (IgG) removal (−86% versus baseline) was achieved after 3 apheresis treatments on 3 consecutive days. The treatments were well tolerated. Safety laboratory parameters did not show unexpected or pathological changes. The effects were transient, with most parameters exhibiting complete recovery between treatments. Minimal complement activation and moderate transient fibrinogen depletion were observed. Immunoadsorption with LIGASORB® provides a safe and effective treatment alternative to TPE in acute episodes of peripheral neurological diseases mediated by pathogenic IgG autoantibodies.
Endocrine Journal | 2015
Birgit Harbeck; Swantje Brede; Claudia Witt; Sven Süfke; Hendrik Lehnert; Christian S. Haas
Nephrology Dialysis Transplantation | 2016
Inge Derad; Birgit Obermann; Alexander Katalinic; Nora Eisemann; Johannes K.-M. Knobloch; Friedhelm Sayk; Peter Wellhöner; Hendrik Lehnert; Werner Solbach; Sven Süfke; Jürgen Steinhoff; Martin Nitschke
American journal of cardiovascular disease | 2013
Gunther Weitz; Hendrik Bonnemeier; Sven Süfke; Peter Wellhöner; Hendrik Lehnert; Christoph Dodt
Journal of Investigative Dermatology | 2017
Franziska Hübner; Michael Kasperkiewicz; Diana Knuth-Rehr; Iakov Shimanovich; Sven Süfke; Philip Muck; Detlef Zillikens; Enno Schmidt
Archive | 2013
Gunther Weitz; Hendrik Bonnemeier; Sven Süfke; Peter Wellhöner; Hendrik Lehnert; Christoph Dodt